News
-
-
-
-
-
PRESS RELEASE
ALT5 Sigma Reports Strong Q4 and Full-Year 2024 Results, Achieves Milestones with Record Revenue, 1,000+ Customers, and Strategic Leadership Appointments
ALT5 Sigma Corp achieves record-breaking Q4 with $5.4 million revenue, surpasses 1,000 customer milestone, and appoints Ron Pitters as COO. Financial results and key developments highlighted -
PRESS RELEASE
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia (fitusiran) approved as the first US therapy for hemophilia A or B with or without inhibitors, offering consistent protection with few injections, using unique mechanism to reduce bleeding episodes -
PRESS RELEASE
Communiqué de presse : Qfitlia – premier médicament approuvé aux États-Unis pour le traitement des hémophilies A ou B, avec ou sans inhibiteurs
La FDA approuve Qfitlia, premier médicament pour hémophilies A/B. Protection contre saignements. Taux d'antithrombine abaissé. Mécanisme unique. Qfitlia réduit doses. Disponible en stylo ou flacon -
-
-
PRESS RELEASE
Sword Group : Notice of Convocation to the Shareholders for the Ordinary and Extraordinary General Meeting of the Company on April 28 2025
Notice to shareholders of Sword Group SE for Ordinary and Extraordinary General Meeting on April 28, 2025, including agenda, voting procedures, and shareholder rights
